JOP20210297A1 - مواد وطرق لحث المناعة التي تساهم فيها الخلايا التائية - Google Patents

مواد وطرق لحث المناعة التي تساهم فيها الخلايا التائية

Info

Publication number
JOP20210297A1
JOP20210297A1 JOP/2021/0297A JOP20210297A JOP20210297A1 JO P20210297 A1 JOP20210297 A1 JO P20210297A1 JO P20210297 A JOP20210297 A JO P20210297A JO P20210297 A1 JOP20210297 A1 JO P20210297A1
Authority
JO
Jordan
Prior art keywords
methods
modulating
materials
antibodies
cell mediated
Prior art date
Application number
JOP/2021/0297A
Other languages
English (en)
Inventor
Rajkumar Ganesan
Sanjaya Singh
Iqbal S Grewal
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of JOP20210297A1 publication Critical patent/JOP20210297A1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

يتم توضيح الأجسام المضادة لـ TRGV9 أو شظايا منها رابطة للمستضدات. فضلاً عن أنه يصف كذلك الأحماض النووية التي تشفر الأجسام المضادة، والتركيبات التي تتألف من الأجسام المضادة، وطرق إنتاج الأجسام المضادة، وطرق استخدام الأجسام المضادة لعلاج الأمراض - كالسرطان - أو الوقاية منها.
JOP/2021/0297A 2019-05-08 2020-05-07 مواد وطرق لحث المناعة التي تساهم فيها الخلايا التائية JOP20210297A1 (ar)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201962844966P 2019-05-08 2019-05-08
US201962844976P 2019-05-08 2019-05-08
US201962844970P 2019-05-08 2019-05-08
US201962844995P 2019-05-08 2019-05-08
US201962844959P 2019-05-08 2019-05-08
PCT/US2020/031749 WO2020227457A1 (en) 2019-05-08 2020-05-07 Materials and methods for modulating t cell mediated immunity

Publications (1)

Publication Number Publication Date
JOP20210297A1 true JOP20210297A1 (ar) 2023-01-30

Family

ID=73051172

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2021/0297A JOP20210297A1 (ar) 2019-05-08 2020-05-07 مواد وطرق لحث المناعة التي تساهم فيها الخلايا التائية

Country Status (21)

Country Link
US (2) US11667712B2 (ar)
EP (1) EP3965818A4 (ar)
JP (1) JP2022533538A (ar)
KR (1) KR20220017892A (ar)
CN (1) CN113966231A (ar)
AU (1) AU2020267504A1 (ar)
BR (1) BR112021022089A2 (ar)
CA (1) CA3139508A1 (ar)
CL (1) CL2021002905A1 (ar)
CO (1) CO2021015998A2 (ar)
CR (1) CR20210548A (ar)
DO (1) DOP2021000229A (ar)
EC (1) ECSP21087921A (ar)
IL (1) IL287817A (ar)
JO (1) JOP20210297A1 (ar)
MA (1) MA55903A (ar)
MX (1) MX2021013532A (ar)
PE (1) PE20220763A1 (ar)
SG (1) SG11202112021QA (ar)
TW (1) TW202108618A (ar)
WO (1) WO2020227457A1 (ar)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3209454A1 (en) 2021-02-26 2022-09-01 Robertus Cornelis ROOVERS Antibodies that bind cd123 and gamma-delta t cell receptors

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
JP2005538682A (ja) 2001-12-03 2005-12-22 アブジェニックス・インコーポレーテッド カルボキシックアンヒドラーゼｉｘ（ｃａｉｘ）腫瘍抗原に対する抗体
JP2008511337A (ja) 2004-09-02 2008-04-17 ジェネンテック・インコーポレーテッド ヘテロ多量体分子
JP5620626B2 (ja) 2005-03-31 2014-11-05 中外製薬株式会社 会合制御によるポリペプチド製造方法
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
AR060070A1 (es) 2006-03-24 2008-05-21 Merck Patent Gmbh Dominios proteicos heterodimericos obtenidos por ingenieria
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
AU2008282218A1 (en) 2007-07-31 2009-02-05 Medimmune, Llc Multispecific epitope binding proteins and uses thereof
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
WO2010045340A1 (en) 2008-10-14 2010-04-22 Centocor Ortho Biotech Inc. Methods of humanizing and affinity-maturing antibodies
ES2708124T3 (es) 2009-04-27 2019-04-08 Oncomed Pharm Inc Procedimiento para preparar moléculas heteromultiméricas
MX353186B (es) * 2009-09-03 2018-01-05 Genentech Inc Metodos para el tratamiento, diagnosis y monitoreo de artritis reumatoide.
WO2011131746A2 (en) 2010-04-20 2011-10-27 Genmab A/S Heterodimeric antibody fc-containing proteins and methods for production thereof
NZ607615A (en) 2010-08-05 2015-03-27 Anaptysbio Inc Antibodies directed against il-17
EP2635607B1 (en) 2010-11-05 2019-09-04 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the fc domain
ES2857734T3 (es) 2011-08-23 2021-09-29 Roche Glycart Ag Moléculas de unión a antígeno activadoras de linfocitos T biespecíficas
JP6326371B2 (ja) 2011-11-04 2018-05-16 ザイムワークス，インコーポレイテッド Ｆｃドメインにおける変異を有する安定なヘテロ二量体抗体デザイン
BR112014015018A2 (pt) 2011-12-19 2020-10-27 Synimmune Gmbh moléculas de anticorpo biespecífico e seu método de produção, bem como composição farmacêutica e molécula de ácido nucleico
KR20160068960A (ko) * 2013-10-25 2016-06-15 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 면역요법을 위한 다클론성 감마 델타 t 세포
WO2015156673A1 (en) 2014-04-10 2015-10-15 Stichting Vu-Vumc IMMUNOGLOBULINS BINDING HUMAN Vγ9Vδ2 T CELL RECEPTORS
PT3303394T (pt) 2015-05-29 2020-07-01 Ludwig Inst For Cancer Res Ltd Anticorpos anti-ctla-4 e métodos de uso dos mesmos
CA3048601A1 (en) 2016-12-26 2018-07-05 Kyowa Hakko Kirin Co., Ltd. Antibody which binds to myelin oligodendrocyte glycoprotein
US11236145B2 (en) * 2017-03-23 2022-02-01 Immatics Biotechnologies Gmbh T cell receptors and immune therapy using the same against PRAME positive cancers
US10519236B2 (en) 2018-01-23 2019-12-31 New York University Antibodies specific to delta 1 chain of T cell receptor
CN115484981A (zh) 2020-02-27 2022-12-16 詹森生物科技公司 用于调节免疫应答的材料和方法
US20210284731A1 (en) 2020-03-13 2021-09-16 Janssen Biotech, Inc. Methods and materials for modulating an immune response
CN116390950A (zh) 2020-10-28 2023-07-04 詹森生物科技公司 用于调节δγ链介导的免疫的组合物和方法

Also Published As

Publication number Publication date
WO2020227457A1 (en) 2020-11-12
CO2021015998A2 (es) 2021-12-10
BR112021022089A2 (pt) 2022-02-08
AU2020267504A1 (en) 2021-12-02
IL287817A (en) 2022-01-01
CN113966231A (zh) 2022-01-21
MX2021013532A (es) 2022-02-11
SG11202112021QA (en) 2021-11-29
CA3139508A1 (en) 2020-11-12
US11667712B2 (en) 2023-06-06
US20240150464A1 (en) 2024-05-09
KR20220017892A (ko) 2022-02-14
JP2022533538A (ja) 2022-07-25
EP3965818A4 (en) 2023-05-31
MA55903A (fr) 2022-03-16
US20210032338A1 (en) 2021-02-04
PE20220763A1 (es) 2022-05-16
EP3965818A1 (en) 2022-03-16
CL2021002905A1 (es) 2022-06-17
CR20210548A (es) 2022-02-11
TW202108618A (zh) 2021-03-01
ECSP21087921A (es) 2022-01-31
DOP2021000229A (es) 2022-07-31

Similar Documents

Publication Publication Date Title
MX2020009366A (es) Anticuerpos anti-cd73 y usos de los mismos.
ZA202004730B (en) Anti-claudin 18.2 antibodies and uses thereof
PH12020552010A1 (en) Anti-cd33 antibodies, anti-cd33/anti-cd3 bispecific antibodies and uses thereof
PH12019501973A1 (en) Anti-phf-tau antibodies and uses thereof
PH12020551907A1 (en) Antagonizing cd73 antibody
ZA202005259B (en) Anti-ctla4 antibodies and methods of making and using the same
MX2022004042A (es) Proteinas de union multiespecificas para tratamiento contra el cancer.
MX2022011732A (es) Conjugados de farmacos y anticuerpos anti-ccr7.
AU2019415848A8 (en) Claudin18.2 binding moieties and uses thereof
PH12019500122A1 (en) Bispecific antibody-like binding proteins specifically binding to cd3 and cd123
WO2019217145A8 (en) Anti-dll3 antibodies and uses thereof
PH12019500571A1 (en) Anti-pd-1 antibodies
MX2022010664A (es) Materiales y métodos para modular una respuesta inmunitaria.
MX2023002945A (es) Moléculas multiespecíficas con direccionamiento inmunitario y usos de estas.
MX2020009522A (es) Anticuerpos anti-folato del receptor 1 y usos de los mismos.
MX2022012628A (es) Anticuerpos anti-phf-tau y usos de estos.
MX2020001287A (es) Receptor de linfocitos t (tcrs) especificos de braf y usos de los mismos.
MX2019014400A (es) Inmunoglobulinas que se unen a adamts.
MX2023002948A (es) Métodos y composiciones para modular la inmunidad mediada por cadena beta.
EP4023674A3 (en) Anti-il-22r antibodies
MX2022015966A (es) Anticuerpos y metodos para tratar enfermedades asociadas a claudina.
CR20210548A (es) Materiales y métodos para modular la inmunidad mediada por células t
WO2021058711A3 (en) Antigen binding proteins
EA202193035A1 (ru) Материалы и способы для модуляции иммунитета, опосредованного т-клетками
EA202092121A1 (ru) Антитела против cd73 и их применения